Nuvectis Pharma, Inc. Segments Disclosure
NOTE 9 – SEGMENT REPORTING:
| a. | The Company operates in one reportable segment: clinical development. The clinical development segment facilitates the development of potential new drug compounds, and its business is unified for the purposes of valuation of its performance. |
Management does not segregate its business for internal reporting. The Company's Chief Operating Decision Maker (“CODM”), who is the CEO evaluates the Company's performance based on its unified internal reporting which is consistent with the presentation in the Company’s financial statements.
Net loss is used to monitor budget versus actual results.
The CODM uses many quantitative and qualitative factors including net loss, and quarterly cash burn in benchmarking the Company to its competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment and in establishing management’s compensation.
Significant segment expenses are presented in the Company’s statements of operations. Additional disaggregated significant segment expenses on a functional basis, that are not separately presented on the Company’s statements of operations, are presented below:
For the Year Ended December 31, | |||||||
2025 | 2024 | ||||||
R&D Employee Expenses | $ | 7,966 | $ | 6,892 | |||
R&D Clinical Trial Expenses | 5,461 | 4,330 | |||||
R&D Professional Fees | 157 | 156 | |||||
R&D Manufacturing | 2,131 | 1,535 | |||||
R&D License Fees | 2,438 | 5 | |||||
G&A Professional Fees | 5,253 | 3,462 | |||||
G&A Employee Expenses | 2,421 | 2,091 | |||||
G&A Insurance | 599 | 606 | |||||
Other Segment Items * | 16 | (77) | |||||
Segment Loss | $ | 26,442 | $ | 19,000 | |||
* - Other Segment Items included in net loss includes interest income, travel and entertainment expenses, printing and information technology expenses.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 11, 2026 | Showing above |
| 2024 | Feb 25, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.